This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Woo PC, Huang Y, Lau SK, Yuen KY "Coronavirus genomics and bioinformatics analysis". Viruses. August 2010. 2 (8): 1804–20. doi:10.3390/v2081803. PMC 3185738. PMID 21994708. Coronaviruses possess the largest genomes (26.4 kb (ThCoV HKU12) to 31.7 kb (SW1)) among all known RNA viruses (Figure 1) (2,13,16).WooPCHuangYLauSKYuenKY"Coronavirus genomics and bioinformatics analysis"August201028180420doi10.3390/v2081803PMC 3185738. PMID 21994708. Coronaviruses possess the largest genomes (26.4 kb (ThCoV HKU12) to 31.7 kb (SW1)) among all known RNA viruses (Figure 1) (2,13,16)318573821994708Open DOISearch in Google Scholar
Novel Ehrlichia Strain Infecting Cattle Tick Amblyomma neumanni, Argentina, 2018 Lucía Fargnoli, Camilo Fernandez, Lucas D. Monje Author affiliation: Instituto de Ciencias Veterinarias del Litoral, UNL-CONICET, Esperanza, Argentina DOI: https://doi.org/10.3201/eid2605.190940ArgentinaDOIhttps://doi.org/10.3201/eid2605.19094010.3201/eid2605.190940718190632310066Search in Google Scholar
Coronaviruses. Niaid.nih.gov 2021. Retrieved 23 May 2021, from https://www.niaid.nih.gov/diseases-conditions/coronavirusesCoronavirusesNiaid.nih.gov2021Retrieved 23 May 2021, fromSearch in Google Scholar
Parry, N. COVID-19 and pets: When pandemic meets panic. Forensic Science International 2020: Reports, 2, 100090. https://doi.org/10.1016/j.fsir.2020.100090ParryNCOVID-19 and pets: When pandemic meets panic2020Reports, 2, 100090https://doi.org/10.1016/j.fsir.2020.10009010.1016/j.fsir.2020.100090Search in Google Scholar
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. "The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2". Nature Microbiology. March 2020. 5 (4): 536–544. Doi:10.1038/s41564-020-0695-z. PMC 7095448. PMID 32123347.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2"March202054536544Doi10.1038/s41564-020-0695-zPMC 7095448. PMID 32123347709544832123347Open DOISearch in Google Scholar
"Coronavirus disease named Covid-19". BBC News Online. 11 February 2020. Archived from the original on 15 February 2020. Retrieved 15 February 2020."Coronavirus disease named Covid-19"11 February 2020. Archived from the original on 15 February 2020. Retrieved 15 February2020Search in Google Scholar
Ozsahin, I., Sekeroglu, B., Musa, M., Mustapha, M., & Uzun Ozsahin, D. Review on Diagnosis of COVID-19 from Chest CT Images Using Artificial Intelligence. Computational and Mathematical Methods in Medicine, 2020, 1-10. https://doi.org/10.1155/2020/9756518OzsahinI.SekerogluB.MusaM.MustaphaM.&Uzun OzsahinDReview on Diagnosis of COVID-19 from Chest CT Images Using Artificial Intelligence2020110https://doi.org/10.1155/2020/975651810.1155/2020/9756518751998333014121Search in Google Scholar
"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 2021-04-24.Johns Hopkins UniversityRetrieved 2021-04-24Search in Google Scholar
"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 2021-04-24.Johns Hopkins UniversityRetrieved 2021-04-24Search in Google Scholar
Santacroce, L., Charitos, I., Carretta, D., De Nitto, E., & Lovero, R. The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. Journal of Molecular Medicine, 2020. 99(1), 93-106. https://doi.org/10.1007/s00109-020-02012-8SantacroceL.CharitosI.CarrettaD.De NittoE.&LoveroR.The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection202099193106https://doi.org/10.1007/s00109-020-02012-810.1007/s00109-020-02012-8771036833269412Search in Google Scholar
Cohen J (2020-01-26). "Wuhan seafood market may not be the source of the novel virus spreading globally". ScienceMag American Association for the Advancement of Science. (AAAS). Archived from the original on 2020-01-27. Retrieved 2020-01-29.CohenJ2020-01-26"Wuhan seafood market may not be the source of the novel virus spreading globally"Archived from the original on 2020-01-27. Retrieved 2020-01-2910.1126/science.abb0611Search in Google Scholar
Eschner K (2020-01-28). "We're still not sure where the COVID-19 really came from". Popular Science. Archived from the original on 2020-01-30. Retrieved 2020-01-30.EschnerK2020-01-28Popular Science. Archived from the original on 2020-01-30. Retrieved 2020-01-3010.51449/AJPR.2020.1101Search in Google Scholar
Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control. (2021). Retrieved 1 May 2021, from https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical2021Retrieved 1 May 2021, fromhttps://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinicalSearch in Google Scholar
Benefits of Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention. (2021). Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html2021Retrieved 23 May 2021, fromhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.htmlSearch in Google Scholar
Luo, R., Delaunay‐Moisan, A., Timmis, K., & Danchin, A. SARS‐CoV ‐2 biology and variants: anticipation of viral evolution and what needs to be done. Environmental Microbiology, 2021. 23(5), 2339-2363. https://doi.org/10.1111/1462-2920.15487LuoR.Delaunay‐MoisanA.TimmisK.&DanchinA.SARS‐CoV ‐2 biology and variants: anticipation of viral evolution and what needs to be done202123523392363https://doi.org/10.1111/1462-2920.1548710.1111/1462-2920.15487825135933769683Search in Google Scholar
Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E., & Kyriakopoulos, A. et al. Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?. Medicina, 2021.57(3), 253. https://doi.org/10.3390/medicina57030253DoulberisM.PapaefthymiouA.KotronisG.GialamprinouD.SoteriadesE.&KyriakopoulosA.et alDoes COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?2021573253https://doi.org/10.3390/medicina5703025310.3390/medicina57030253799935633803295Search in Google Scholar
Brans, J., & Vincke, P. Note- A Preference Ranking Organization Method. Management Science, 1985, 31(6), 647-656. https://doi.org/10.1287/mnsc.31.6.647BransJ.&VinckePNote- A Preference Ranking Organization Method1985316647656https://doi.org/10.1287/mnsc.31.6.64710.1287/mnsc.31.6.647Search in Google Scholar
Macharis, C., Springael, J., De Brucker, K., & Verbeke, A. PROMETHEE and AHP: The design of operational synergies in multi-criteria analysis. European Journal of Operational Research, 2004. 153(2), 307-317. https://doi.org/10.1016/s0377-2217 (03)00153-x.MacharisC.SpringaelJ.De BruckerK.&VerbekeA.PROMETHEE and AHP: The design of operational synergies in multi-criteria analysis20041532307317https://doi.org/10.1016/s0377-2217(03)00153-x10.1016/S0377-2217(03)00153-XSearch in Google Scholar
Wouters, O., Shadlen, K., Salcher-Konrad, M., Pollard, A., Larson, H., Teerawattananon, Y., & Jit, M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 2021. 397(10278), 1023-1034. https://doi.org/10.1016/s0140-6736 (21)00306-8.WoutersO.ShadlenK.Salcher-KonradM.PollardA.LarsonH.TeerawattananonY.&JitMChallenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment20213971027810231034https://doi.org/10.1016/s0140-6736(21)00306-810.1016/S0140-6736(21)00306-8Search in Google Scholar
Abdullah, L., Chan, W., & Afshari, A.. Application of PRO-METHEE method for green supplier selection: a comparative result based on preference functions. Journal of Industrial Engineering International, 2018. 15(2), 271-285. https://doi.org/10.1007/s40092-018-0289-zAbdullahL.ChanW.&AfshariA.Application of PRO-METHEE method for green supplier selection: a comparative result based on preference functions2018152271285https://doi.org/10.1007/s40092-018-0289-z10.1007/s40092-018-0289-zSearch in Google Scholar
Nakajima, Y., Fujii, T., Mukai, K., Ishida, A., Kato, M., & Takahashi, M. et al. Anatomically safe sites for intramuscular injections: a cross-sectional study on young adults and cadavers with a focus on the thigh. Human Vaccines & Immunotherapeutics, 2019. 16(1), 189-196. https://doi.org/10.1080/21645515.2019.1646576NakajimaY.FujiiT.MukaiK.IshidaA.KatoM.&TakahashiM.et alAnatomically safe sites for intramuscular injections: a cross-sectional study on young adults and cadavers with a focus on the thigh2019161189196https://doi.org/10.1080/21645515.2019.164657610.1080/21645515.2019.1646576Search in Google Scholar
Cdc.gov (2021). Retrieved 23 May 2021, from https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-understand-color-office.pdfCdc.gov2021Retrieved 23 May 2021, fromSearch in Google Scholar
Ryzhikov, A., Ryzhikov, Е., Bogryantseva, M., Usova, S., Danilenko, E., & Nechaeva, E. et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity, 2021. 11(2), 283-296. https://doi.org/10.15789/2220-7619-asb-1699RyzhikovA.RyzhikovЕ.BogryantsevaM.UsovaS.DanilenkoE.&NechaevaE.et alA single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)2021112283296https://doi.org/10.15789/2220-7619-asb-169910.15789/2220-7619-ASB-1699Search in Google Scholar
Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 - Full Text View - ClinicalTrials. gov. Clinicaltrials.gov 2021. Retrieved 23 May 2021, from https://clinicaltrials.gov/ct2/show/NCT04780035Clinicaltrials.gov2021Retrieved 23 May 2021, fromhttps://clinicaltrials.gov/ct2/show/NCT04780035Search in Google Scholar
All you need to know about COVID-19 and Vaccines (National Institute for Communicable Diseases). 2021. 3(1), 77. https://doi.org/10.18772/26180197.2021.v3n1a1620213177https://doi.org/10.18772/26180197.2021.v3n1a1610.18772/26180197.2021.v3n1a16Search in Google Scholar
How Gamaleya’s Vaccine Works. Nytimes.com 2021. Retrieved 23 May 2021, from https://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.htmlNytimes.com2021Retrieved 23 May 2021, fromhttps://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.htmlSearch in Google Scholar
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. U.S. Food and Drug Administration. 2021. Retrieved 23 May 2021, from https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covidRetrieved 23 May 2021, fromhttps://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covidSearch in Google Scholar
Information about the Pfizer-BioNTech COVID-19 Vaccine. Centers for Disease Control and Prevention. 2021. Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.htmlInformation about the Pfizer-BioNTech COVID-19 Vaccine2021Retrieved 23 May 2021, fromhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.htmlSearch in Google Scholar
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. October 2020. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.XiaSZhangYWangYWangHYangYGaoGFet al"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"October20202113951doi10.1016/s1473-3099(20)30831-8.PMC7561304.PMID33069281Open DOISearch in Google Scholar
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al.. "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. September 2020.324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.XiaSDuanKZhangYZhaoDZhangHXieZet al"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials"September202032410951960doi10.1001/jama.2020.15543PMC 7426884. PMID 32789505742688432789505Open DOISearch in Google Scholar
Vergara, Eva. "Big Chile study finds Chinese vaccine slashes COVID deaths". ABC News. Retrieved 16 April 2021.VergaraEva"Big Chile study finds Chinese vaccine slashes COVID deaths"Retrieved 16 April2021Search in Google Scholar